← Back to Search

Insulin

Ultra-rapid insulin for Type 1 Diabetes

N/A

Waitlist Available

Led By Rayhan Lal, MD

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up peritoneal: every 5 minutes for 180 minutes max; subcutaneous: every 15 minutes for 360 minutes max

Awards & highlights

Study Summary

This trial will study the effects of injecting insulin into the peritoneum, as opposed to subcutaneously. They will measure glucose, insulin and glucagon levels to see if there are any benefits to this method.

Eligible Conditions

Type 1 Diabetes

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ peritoneal: every 5 minutes for 180 minutes max; subcutaneous: every 15 minutes for 360 minutes max

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~peritoneal: every 5 minutes for 180 minutes max; subcutaneous: every 15 minutes for 360 minutes max

This trial's timeline: 3 weeks for screening, Varies for treatment, and peritoneal: every 5 minutes for 180 minutes max; subcutaneous: every 15 minutes for 360 minutes max for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Glucagon response to induced hypoglycemia

Secondary outcome measures

Glucose Values

Insulin concentration in plasma

Trial Design

2Treatment groups

Experimental Treatment

Group I: Upper Peritoneal, then Lower Peritoneal, then SubcutaneousExperimental Treatment1 Intervention

Ultra-fast acting insulin will be injected into the upper peritoneum then lower peritoneum then subcutaneous space.

Group II: Lower Peritoneal, then Upper Peritoneal, then SubcutaneousExperimental Treatment1 Intervention

Ultra-fast acting insulin will be injected into the lower peritoneum then upper peritoneum then subcutaneous space.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Institutes of Health (NIH)NIH

2,696 Previous Clinical Trials

6,952,563 Total Patients Enrolled

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH

2,357 Previous Clinical Trials

4,315,170 Total Patients Enrolled

Stanford UniversityLead Sponsor

2,387 Previous Clinical Trials

17,334,034 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants of advanced age eligible for this trial?

"The minimum age requirement to be included in this investigation is 18 and the upper limit is 60 years old, as stipulated by the criteria for entry."

Answered by AI

How many participants are being monitored for this clinical experiment?

"Affirmative. Information posted on clinicaltrials.gov indicates that the trial is currently recruiting patients, with its initial posting taking place November 1st 2021 and last edit being made April 18th 2022. 15 individuals must be enrolled from one particular medical centre."

Answered by AI

Who is a qualified contender for this clinical investigation?

"This trial is open to 15 individuals who suffer from diabetes and other autoimmune issues, between 18-60 years of age. Additionally, those hoping to qualify are expected to have used an insulin pump and CGM for at least 3 months; females must be able to prove that they are not pregnant."

Answered by AI

Are there still slots available for participation in this experiment?

"Affirmative, according to information on clinicaltrials.gov the research project is actively recruiting participants. It was first advertised on November 1st 2021 and its most recent update was issued April 18th 2022; requiring 15 people from a single trial centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluating the Benefits of Physiologic Insulin Delivery

Rayhan A. Lal 2021. "Evaluating the Benefits of Physiologic Insulin Delivery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04416737.